Samsung Biologics' board approved a roughly 3 trillion won $2.18 billion rights offering to fund its acquisition of PolyPeptide Group and expand its Songdo bio campus. The 2.27 million new shares, priced at an expected 1.32 million won each, direct 2.71 trillion won into peptide manufacturing…
On August 28, 2026, the board of Samsung Biologics approved a paid-in capital increase of roughly 3 trillion won, about $2.18 billion, to be raised through a rights offering of 2.27 million new shares expected to price at 1.32 million won each. The company announced the move and filed a disclosure with South Korea's Financial Supervisory Service the same day. Of the proceeds, 2.71 trillion won is earmarked for the acquisition of Switzerland-based PolyPeptide Group, and 294.8 billion won for expansion of the company's second bio campus in Songdo, Incheon. The acquisition, valued at 1.46 billion Swiss francs, about $1.81 billion, was first announced in July 2026 and is expected to become the largest deal in the history of Korea's pharmaceutical and biotech industry. Jeong Hye-jeong, a reporter at the Korea JoongAng Daily, covered the disclosure and the company's comments on it.
A paid-in capital increase is the mechanism by which a listed Korean company issues new shares and collects cash against them. In this case the issuance is structured as a rights offering, which means the 2.27 million new shares will first be offered to existing shareholders in proportion to their current holdings, and any shares they do not take up will be offered to the public. The board resolution sets the terms of the offering and states the use of proceeds. That is why the August 28 filing matters: it converts a July strategy announcement about buying PolyPeptide Group into a specific financing plan with a share count, a price expectation, and a use of funds. The two earmarked uses, 2.71 trillion won for the acquisition and 294.8 billion won for the campus, sum to approximately the size of the offering.
PolyPeptide Group is a contract manufacturer that specializes in peptide synthesis , and Samsung Biologics has said the purchase is its route into the fast-growing market for GLP-1 treatments for obesity and diabetes. The deal adds peptides to a portfolio that already includes antibody drugs, messenger RNA, and antibody-drug conjugates, and it gives Samsung Biologics access to PolyPeptide manufacturing sites in Europe, the United States, and India. In a company statement, Samsung Biologics said: "We are raising capital to acquire PolyPeptide Group and expand our second bio campus in Songdo, Incheon."
The financing structure is the new detail. Samsung Biologics announced the PolyPeptide acquisition in July 2026, but the mechanism for paying for the deal, and for the parallel construction program at the Incheon campus, was not disclosed until the board resolution on August 28. The rights offering funds both commitments at once, and the company frames it as an advance on its goal of becoming a world-leading contract development and manufacturing organization, or CDMO .
The rights offering gives existing shareholders the right to subscribe to 2.27 million new shares, which equal roughly 4.9 percent of Samsung Biologics' existing share count. The expected price of 1.32 million won per share values the issue at approximately 3 trillion won. Because 2.27 million shares is 4.9 percent of the pre-offering base, the existing base is roughly 46.3 million shares and the enlarged total would be about 48.6 million. A shareholder who subscribes in full preserves proportional ownership. A shareholder who subscribes to nothing sees their stake fall from its current percentage to roughly 95 percent of that percentage, which is about 4.7 percent dilution measured on the enlarged base. That arithmetic is the basis for the company's estimate. An unnamed Samsung Biologics official said: "The new shares will represent about five percent of existing shares, so we expect limited dilution for shareholders."
The same official said: "The rights offering will give us the funds to invest in growth and greater financial flexibility as competition and uncertainty intensify across the global CDMO industry."
Both headline figures carry qualifiers. The 1.32 million won per-share price is the expected price, not the final one, and the roughly 3 trillion won total is a projection based on it. Rights offerings of this type are priced by reference to the market price during the subscription window, typically at a discount, so the final price will move with Samsung Biologics shares between now and the offering. A higher final price would raise more capital for the same number of shares; a lower one would raise less. Samsung Biologics has not said how it would cover any shortfall.
Why raise equity rather than borrow? A rights offering carries no interest expense and puts the funding burden on shareholders in proportion to their ownership. It also tests shareholder conviction. Strong subscription delivers the capital and leaves the ownership structure unchanged. Weak subscription pushes unsubscribed shares to the public, shifts ownership toward new investors, and can leave the company with less than the targeted proceeds. The about 5 percent dilution estimate assumes full subscription.
The regulatory event at the center of the announcement is a corporate disclosure to the Financial Supervisory Service, South Korea's financial regulator. Listed Korean companies are required to file a board resolution on a paid-in capital increase, and the filing commits Samsung Biologics to carry out the offering on the disclosed terms. The rights offering follows the standard Korean sequence: a board resolution, a subscription period for existing shareholders, and a fallback public offering for any unsubscribed shares. The disclosure fixes the share count, the expected price, and the stated use of proceeds, all material facts for investors deciding whether to subscribe.
The capital increase and the acquisition sit in separate regulatory lanes. The FSS filing governs the securities offering. The purchase of PolyPeptide Group is a cross-border transaction involving a Swiss target with contract manufacturing plants in Europe, the United States, and India. A deal of this size typically requires merger control clearance in the jurisdictions where the target operates and where the buyer is based, plus foreign investment and foreign exchange filings for a Korean company moving capital abroad. Samsung Biologics has not enumerated the approvals it expects to need, and its plan to close the acquisition by the end of 2026 is conditional on the rights offering succeeding and on whatever clearances emerge.
That conditionality creates a sequencing risk. The subscription period runs on a fixed calendar, the newly issued shares are listed, and only then does the company have the roughly 3 trillion won in hand. The earmarked 2.71 trillion won is the designated funding source for the 1.46 billion Swiss franc purchase price. If clearance is delayed or a condition fails, Samsung Biologics would hold cash earmarked for a target it cannot yet buy. The company has not said what would happen to the funds in that scenario.
PolyPeptide Group is a Switzerland-based CDMO whose core business is contract peptide synthesis. Commercial peptide drugs are built by solid-phase chemistry rather than cell culture, and the manufacturing skill sits in the chemistry: coupling yields, purification trains, and GMP controls that keep impurity profiles inside regulatory limits. PolyPeptide runs peptide manufacturing sites in Europe, the United States, and India, a distributed network with the geographic redundancy that pharmaceutical customers require for commercial supply. Those sites are what Samsung Biologics is paying 1.46 billion Swiss francs, about $1.81 billion, to own.
The earmark allocation shows where the money is going. The 2.71 trillion won set aside for the acquisition is roughly 90 percent of the 3 trillion won offering, which makes the purchase the dominant purpose of the raise. The Songdo campus build-out, funded with 294.8 billion won, is the smaller commitment.
For a company whose manufacturing expertise sits in stainless steel bioreactors and mammalian cell culture, the fit is less obvious than the strategic logic. Peptide plants and antibody plants share little equipment. Solid-phase synthesis uses resin reactors and preparative high-performance liquid chromatography columns; antibody production uses seed trains, bioreactors, and downstream protein purification. The workforce, the quality systems, and the regulatory dossiers are different. What Samsung Biologics is buying is a second manufacturing discipline, a set of customer relationships, and a validated GMP network across three regions, plus peptide know-how that would otherwise take years to build.
The deal does not give Samsung Biologics a GLP-1 drug of its own. It gives the company manufacturing capacity for hire, which is the CDMO model. The July 2026 announcement of the acquisition cited the GLP-1 treatment market directly. The company's stated strategy covers all three legs of the purchase: peptide portfolio, geographic footprint, and production capacity.
The 294.8 billion won earmarked for the Songdo second bio campus funds a specific build-out. Samsung Biologics plans four new production plants of 180,000 liters each at the campus in Incheon, which together add 720,000 liters of cell culture capacity. With that expansion, the company projects total antibody drug production capacity of 1.385 million liters . The projection implies a current installed base of roughly 665,000 liters, since 1.385 million minus the 720,000 liters the four plants will add leaves that amount. Samsung Biologics' Songdo headquarters in Incheon, the site of the expansion, was photographed on June 28.
The scale is the point. Antibody drugs are produced in mammalian cell culture, typically in Chinese hamster ovary cells growing in large stainless steel bioreactors, and capacity is measured the way a refinery measures throughput. A 180,000-liter plant sits at the top end of commercial bioreactor scale, and four of them represent a multiyear construction program with a capital intensity that few CDMOs can match. The second campus expansion is the production capacity leg of the strategy the company described in its statement: "The investment will support sustainable growth, and our three-pronged expansion strategy is focused on production capacity, portfolio and geographic footprint."
The arithmetic of what that capacity can produce is straightforward. Commercial fed-batch antibody processes at this scale typically achieve titers of two to five grams per liter. At three grams per liter, a fully utilized 1.385 million liters would support more than 4,000 kilograms of antibody output per year before downstream purification losses. That volume would put the company in the top tier of contract antibody manufacturers. The projection assumes the four plants are built, validated, and filled with customer contracts, none of which the company has scheduled in detail.
The strategic logic runs through GLP-1 biology. Glucagon-like peptide-1 is an incretin hormone released from intestinal L cells after food intake. It binds the GLP-1 receptor on pancreatic beta cells and potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central circuits that reduce appetite. Because the insulin response is glucose-dependent, the risk of hypoglycemia is lower than with older diabetes drugs, and the weight-loss effect has made the class one of the best-selling pharmaceutical categories in the world.
Native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4, so the marketed drugs are stabilized analogs with much longer…
Peptides referenced: Glucagon, GLP-1.
Related reading: Viva Biotech Ties Hybrid Synthesis to AI for Peptide Scale-Up, Piramal Pharma adds spray drying suite at Turbhe peptide site, Neoantigen peptide vaccines face a purity-testing standards gap, Manufacturing bottlenecks stall personalized neoantigen peptide vaccines.